Form 4: Atwood Acquires Pre-Funded Warrants and Common Stock Warrants in Cero Therapeutics Holdings

Brian G. Atwood, a director of Cero Therapeutics Holdings, acquired pre-funded warrants and warrants to purchase common stock on February 7, 2025.

Summary

• On February 7, 2025, Brian G. Atwood, a director of Cero Therapeutics Holdings, Inc., acquired pre-funded warrants and warrants to purchase common stock.
• The pre-funded warrants are exercisable at $0.0001 per share.
• The warrants will become exercisable upon stockholder approval at $1.96 per share.
• Atwood directly acquired 306,120 pre-funded warrants and 306,120 warrants.
• Through GVN, LLC, Atwood indirectly acquired 204,080 pre-funded warrants and 204,080 warrants.
• The aggregate purchase price for each pair of pre-funded warrants and warrants was $1.9599.
• The warrants will expire five years after the stockholder approval date.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a transaction. The insider participation could be seen as a positive signal, but it's not overwhelmingly so.

Positives

• Insider participation may signal confidence in the company's future prospects.

Risks

• The warrants are contingent on stockholder approval, which introduces uncertainty.

Future Outlook

The warrants will become exercisable upon the Issuer's receipt of stockholder approval, and will expire on the fifth anniversary of the Stockholder Approval Date.

Industry Context

This is a common practice for incentivizing company directors and aligning their interests with those of shareholders.

Comparison to Industry Standards

• Warrant structures are common in the biotech industry, particularly for smaller companies seeking funding.
• The exercise prices and terms are within the typical range for such instruments.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution if the warrants are exercised.
• The transaction aligns the director's interests with those of the shareholders.

Next Steps

• Stockholder approval is required for the warrants to become exercisable.

Key Dates

Keywords

Cero Therapeutics Holdings, Brian G. Atwood, pre-funded warrants, warrants, insider trading, beneficial ownership, Form 4